<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480284</url>
  </required_header>
  <id_info>
    <org_study_id>115409</org_study_id>
    <nct_id>NCT01480284</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue</brief_title>
  <official_title>A Multi-center, Randomized, Active Controlled, Double-blind, Parallel Group Comparison Study and Subsequent Open-label Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of GSK548470 administered
      once daily at a dose level of 300 mg to Japanese patients with compensated chronic hepatitis
      B untreated with any nucleic acid analogue. In efficacy, the non-inferiority of GSK548470 to
      ETV will be verified using the antiviral effect as the index.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, active comparator-controlled, double-blind,
      parallel-group comparison study in Japanese patients with compensated chronic hepatitis B
      untreated with any nucleic acid analogue and its subsequent open-label study. Efficacy and
      safety will be compared between once-daily dosing of GSK548470 300 mg and once-daily dosing
      of ETV 0.5 mg, and subsequently the efficacy and safety of GSK548470 administered long term
      will be investigated. A total of 165 subjects will be assigned to the GSK548470 group or the
      ETV group at a ratio of 2:1. The subjects will be assigned by stratified randomization in
      terms of HBe antigen and serum HBV-DNA level. The primary purpose is to verify the
      non-inferiority of GSK548470 to ETV using as an index the change amount of HBV-DNA level at
      Week 24 from the baseline level. The secondary purpose is to investigate the efficacy and
      safety of GSK548470 300 mg administered once daily for a long term.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Serum HBV DNA Level at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The mean change from Baseline in the hepatitis B virus deoxyribonucleic acid (HBV DNA) level at Week 24 was assessed (lower limit of quantitation : 2.1 log 10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Serum HBV DNA Level at Week 48 and Week 96</measure>
    <time_frame>Baseline, Week 48 and Week 96</time_frame>
    <description>The mean change from Baseline in the HBV DNA level at Week 48 and Week 96 were assessed (lower limit of quantitation : 2.1 log10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-baseline value minus the Baseline value. The LOCF method was applied for missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serum HBV DNA &lt; 2.1 log10 Copies/mL at Week 24, Week 48 and Week 96</measure>
    <time_frame>Week 24, Week 48 and Week 96</time_frame>
    <description>The number of participants with serum HBV DNA level less than the lower limit of quantitation (i.e. 2.1 log10 copies/mL) at Week 24, Week 48 and Week 96 were summarized. The LOCF method was applied for missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96</measure>
    <time_frame>Week 24, Week 48 and Week 96</time_frame>
    <description>The number of participants with alanine aminotransferase (ALT) normalization at Week 24, Week 48 and Week 96 were summarized. ALT normalization is defined as when an ALT value exceeds the upper limit of normal range (ULN) at Baseline and within the normal range at the end of treatment. The LOCF method was applied for missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HBeAg Loss at Week 24, Week 48 and Week 96</measure>
    <time_frame>Week 24, Week 48 and Week 96</time_frame>
    <description>The number of participants achieving hepatitis Be antigen (HBeAg) loss at Week 24, Week 48 and Week 96 in positive HBeAg participants at Baseline were summarized. Loss of HBeAg is defined as the change of detectable HBeAg from positive to negative. The LOCF method was applied for missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96</measure>
    <time_frame>Week 24, Week 48 and Week 96</time_frame>
    <description>The number of participants achieving HBeAg/hepatitis Be antibody (HBeAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBeAg and negative HBeAb participants at Baseline were summarized. Seroconversion to HBeAg is defined as the change of detectable antibody to HBeAg from negative to positive. The LOCF method was applied for missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96</measure>
    <time_frame>Week 24, Week 48 and Week 96</time_frame>
    <description>The number of participants with hepatitis B surface antigen (HBsAg) loss at Week 24, Week 48 and Week 96 in positive HBsAg participants at Baseline were summarized. Loss of HBsAg is defined as change of detectable HBsAg from positive to negative. The LOCF method was applied for missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96</measure>
    <time_frame>Week 24, Week 48 and Week 96</time_frame>
    <description>The number of participants with HBsAg/hepatitis B surface antibody (HBsAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBsAg and negative HBsAb participants at Baseline were summarized. HBsAg seroconversion .is defined as change of detectable antibody to HBsAg from negative to positive. The LOCF method was applied for missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96</measure>
    <time_frame>Baseline, Week 24, Week 48 and Week 96</time_frame>
    <description>The number of participants achieving each indicated HBsAg category (HBsAg &lt;80, 80 to 800, 800 to 8000, 8000 to 80000, and &gt;=80000) (kilo international unit per liter [KIU/L]) by study visit was summarized. The LOCF method was applied for missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Each Indicated HBcrAg Category at Baseline, Week 24, Week 48 and Week 96</measure>
    <time_frame>Baseline, Week 24, Week 48 and Week 96</time_frame>
    <description>The number of participants achieving each indicated hepatitis B core-related antigen (HBcrAg) category (HBcrAg &lt;3.0, 3.0 to 4.0, 4.0 to 5.0, 5.0 to 6.0, and &gt;=6.0) (Log kilo unit per liter [KU/L]) by study visit was summarized. The LOCF method was applied for missing values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Virological Breakthrough Through End of the Study</measure>
    <time_frame>From Baseline to throughout study</time_frame>
    <description>The number of participants who experienced virological breakthrough was summarized. Virological breakthrough is defined as serum HBV DNA level increase &gt;=1 log10 copies/mL above the treatment nadir. Virological breakthrough values were presented from Baseline to through out the study. Baseline is defined as the value at Week 0 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Resistance Related Mutations at Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to Throughout the Study)</measure>
    <time_frame>Screening, Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to throughout the study)</time_frame>
    <description>The development of drug resistance-related (RA) mutations was analyzed to look for resistance to Lamivudine (LAM), Adefovir dipivoxil (ADV), and/or ETV in a case where a virologic breakthrough has been observed after starting the study treatment (serum HBV DNA level has increased from the nadir by at least 1 log10 copies/mL) or where the serum HBV DNA level is not less than the HBV DNA detection limit (2.1 log10 copies/mL) at Week 24, Week 48 and Week 96. Virologic breakthrough was defined as 1.0 log10 or greater increases in serum HBV-DNA levels from on-treatment nadir. Participants who achieved the HBV-DNA values below lower limit of quantification (LLQ) (&lt; 2.1 log10 copies/mL) in quantitative analysis at entire the study were also considered &quot;Negative&quot; in drug-resistance without implementation of genotypic analysis. Resistance mutation values were presented from Baseline to throughout the study. Baseline is defined as the value at Week 0 visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>GSK548470 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK548470 300 mg tablet and ETV placebo capsule are administered once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETV 0.5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ETV 0.5 mg capsule and GSK548470 placebo tablet are administered once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK548470 300 mg tablet</intervention_name>
    <description>Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate</description>
    <arm_group_label>GSK548470 300 mg</arm_group_label>
    <other_name>GSK548470</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETV 0.5 mg capsule</intervention_name>
    <description>Brown capsules, each capsule containing 0.53 mg of entecavir hydrate</description>
    <arm_group_label>ETV 0.5 mg</arm_group_label>
    <other_name>ETV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The ability to understand and sign a written informed consent form

          -  16 to 69 years of age at the time of informed consent

          -  Females of childbearing potential must have a negative pregnancy test and agree to
             avoidance of pregnancy

          -  Subject must show QTc &lt; 450 millisecond (msec) or &lt; 480 msec with Bundle Branch Block

          -  Chronic HBV infection, defined as positive serum HBsAg for at least 6 month, or
             negative serum IgM-HBc antibody

          -  HBeAg positive; HBV-DNA &gt;= 6 log10 copies/mL, HBeAg negative; HBV-DNA &gt;= 5 log10
             copies/mL

          -  Serum ALT &gt;= 31 U/L and &lt;= 10 × ULN

          -  Creatinine clearance &gt;= 70 mL/min

          -  Haemoglobin &gt;= 8 g/dL

          -  WBC &gt;= 1,000 /mm3

          -  Nucleic acid analogue naïve, i.e., no prior therapy for over 6 months in the past

          -  No mutation that shows resistance in LAM, ETV and/or TDF at screening

        Exclusion Criteria:

          -  Decompensated liver disease

          -  Co-infection with HIV or HCV

          -  Autoimmune hepatitis rather than chronic hepatitis B

          -  Subject with serious complication

          -  Received or have a plan for solid organ or bone marrow transplantation

          -  Has proximal tubulopathy

          -  History of hypersensitivity to nucleoside and/or nucleotide analogues

          -  Evidence of hepatocellular carcinoma by diagnostic imaging at screening and/or serum
             α-fetoprotein &gt; 50 ng/mL at screening

          -  History of HCC

          -  Received any nucleoside, nucleotide, interferon or HB vaccine therapy within 24 weeks
             prior to initiation

          -  Received overdose NSAIDs, excluding temporary or topical use, within 7 days prior to
             initiation

          -  Received drugs for injection containing glycyrrhizin as the main component within 4
             weeks prior to initiation

          -  Received drugs causing renal impairment, competitors of renal excretion,
             immunosuppressants, chemotherapeutics and/or corticosteroids within 8 weeks prior to
             initiation

          -  Participation in another clinical study within 6 months of study entry or planned
             participation in another clinical study after entry to this study

          -  Woman who is pregnant, lactating, possibly pregnant or planning a pregnancy during the
             study period

          -  Psychiatry disorder or cognitive disorder that may affect the subject ability to give
             informed consent or to follow specified study procedures

          -  History of alcohol or drug abuse

          -  Any condition or situation that may interfere with the subject's participation in the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichi</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukui</city>
        <zip>918-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>803-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8539</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gifu</city>
        <zip>500-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>651-2273</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagawa</city>
        <zip>760-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-8512</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>213-8587</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <zip>862-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyazaki</city>
        <zip>880-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nara</city>
        <zip>630-8305</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>700-0913</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>700-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>564-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saga</city>
        <zip>840-8571</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>140-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2011</study_first_posted>
  <results_first_submitted>August 22, 2013</results_first_submitted>
  <results_first_submitted_qc>August 22, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2013</results_first_posted>
  <last_update_submitted>July 7, 2016</last_update_submitted>
  <last_update_submitted_qc>July 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tenofovir Disoproxil Fumarate</keyword>
  <keyword>Chronic Hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 166 participants (110 participants in the Tenofovir Disoproxil Fumarate [GSK548470, TDF] group and 56 participants in the Entecavir Hydrate [ETV] group) were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TDF 300 mg OD</title>
          <description>Participants received Tenofovir Disoproxil Fumarate (TDF) 300 milligrams (mg) tablet once daily (OD) and Entecavir Hydrate (ETV) placebo capsule OD for 96 weeks.</description>
        </group>
        <group group_id="P2">
          <title>ETV 0.5 mg OD</title>
          <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closed/terminated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TDF 300 mg OD</title>
          <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
        </group>
        <group group_id="B2">
          <title>ETV 0.5 mg OD</title>
          <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="109"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Baseline characteristics are presented for the full analysis set, which is defined as all participants who entered into the study, received at least one dose of investigational product, and have at least one efficacy assessment after the treatment initiation.</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.4" spread="9.23"/>
                    <measurement group_id="B2" value="46.1" spread="9.68"/>
                    <measurement group_id="B3" value="45.6" spread="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Baseline characteristics are presented for the full analysis set, which is defined as all participants who entered into the study, received at least one dose of investigational product, and have at least one efficacy assessment after the treatment initiation.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Baseline characteristics are presented for the full analysis set, which is defined as all participants who entered into the study, received at least one dose of investigational product, and have at least one efficacy assessment after the treatment initiation.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Serum HBV DNA Level at Week 24</title>
        <description>The mean change from Baseline in the hepatitis B virus deoxyribonucleic acid (HBV DNA) level at Week 24 was assessed (lower limit of quantitation : 2.1 log 10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Per Protocol Set (PPS) Population: all participants who received at least 1 dose of investigational product (IP) and had at least one efficacy assessment after the treatment initiation, and with no major protocol violations. Missing values observed during the treatment period were imputed by the last observation carried forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Serum HBV DNA Level at Week 24</title>
          <description>The mean change from Baseline in the hepatitis B virus deoxyribonucleic acid (HBV DNA) level at Week 24 was assessed (lower limit of quantitation : 2.1 log 10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.</description>
          <population>Per Protocol Set (PPS) Population: all participants who received at least 1 dose of investigational product (IP) and had at least one efficacy assessment after the treatment initiation, and with no major protocol violations. Missing values observed during the treatment period were imputed by the last observation carried forward (LOCF) method.</population>
          <units>log10 copies/milliliter (copies/mL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.63" spread="0.044"/>
                    <measurement group_id="O2" value="-4.50" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was judged based on the one-sided test of the model, y(Δ) = Baseline + Group ( Δ= -1.0). The adjusted mean values of the TDF group and the ETV group were calculated, and the adjusted mean value and two-sided 95% confidence interval of differences between the TDF group and the ETV group were calculated. Non-inferiority was also to be confirmed when the upper limit of the calculated two-sided 95% confidence interval was less than the non-inferiority limit value of 1.0</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>p-value was compared with the significance level of 0.025</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Serum HBV DNA Level at Week 48 and Week 96</title>
        <description>The mean change from Baseline in the HBV DNA level at Week 48 and Week 96 were assessed (lower limit of quantitation : 2.1 log10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-baseline value minus the Baseline value. The LOCF method was applied for missing values.</description>
        <time_frame>Baseline, Week 48 and Week 96</time_frame>
        <population>Full Analysis Set (FAS) Population: all participants who entered into the study, received at least one dose of investigational product, and have at least one efficacy assessment after the treatment initiation.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Serum HBV DNA Level at Week 48 and Week 96</title>
          <description>The mean change from Baseline in the HBV DNA level at Week 48 and Week 96 were assessed (lower limit of quantitation : 2.1 log10 copies/mL). The mean values were adjusted by Baseline HBV DNA levels. Change from Baseline was calculated as the post-baseline value minus the Baseline value. The LOCF method was applied for missing values.</description>
          <population>Full Analysis Set (FAS) Population: all participants who entered into the study, received at least one dose of investigational product, and have at least one efficacy assessment after the treatment initiation.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.86" spread="1.353"/>
                    <measurement group_id="O2" value="-4.85" spread="0.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.96" spread="1.445"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
            <estimate_desc>CI and estimate difference is provided for change from Baseline in serum HBV DNA level at Week 48.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serum HBV DNA &lt; 2.1 log10 Copies/mL at Week 24, Week 48 and Week 96</title>
        <description>The number of participants with serum HBV DNA level less than the lower limit of quantitation (i.e. 2.1 log10 copies/mL) at Week 24, Week 48 and Week 96 were summarized. The LOCF method was applied for missing values.</description>
        <time_frame>Week 24, Week 48 and Week 96</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serum HBV DNA &lt; 2.1 log10 Copies/mL at Week 24, Week 48 and Week 96</title>
          <description>The number of participants with serum HBV DNA level less than the lower limit of quantitation (i.e. 2.1 log10 copies/mL) at Week 24, Week 48 and Week 96 were summarized. The LOCF method was applied for missing values.</description>
          <population>FAS Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96</title>
        <description>The number of participants with alanine aminotransferase (ALT) normalization at Week 24, Week 48 and Week 96 were summarized. ALT normalization is defined as when an ALT value exceeds the upper limit of normal range (ULN) at Baseline and within the normal range at the end of treatment. The LOCF method was applied for missing values.</description>
        <time_frame>Week 24, Week 48 and Week 96</time_frame>
        <population>Biochemically Evaluable Population (BEP): all participants who received at least one dose of IP and with an abnormal ALT at Baseline. The population for the analysis of ALT normalization was all participants with an ALT value &gt; ULN at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Alanine Aminotransferase (ALT) Normalization at Week 24, Week 48 and Week 96</title>
          <description>The number of participants with alanine aminotransferase (ALT) normalization at Week 24, Week 48 and Week 96 were summarized. ALT normalization is defined as when an ALT value exceeds the upper limit of normal range (ULN) at Baseline and within the normal range at the end of treatment. The LOCF method was applied for missing values.</description>
          <population>Biochemically Evaluable Population (BEP): all participants who received at least one dose of IP and with an abnormal ALT at Baseline. The population for the analysis of ALT normalization was all participants with an ALT value &gt; ULN at Baseline.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HBeAg Loss at Week 24, Week 48 and Week 96</title>
        <description>The number of participants achieving hepatitis Be antigen (HBeAg) loss at Week 24, Week 48 and Week 96 in positive HBeAg participants at Baseline were summarized. Loss of HBeAg is defined as the change of detectable HBeAg from positive to negative. The LOCF method was applied for missing values.</description>
        <time_frame>Week 24, Week 48 and Week 96</time_frame>
        <population>FAS Population. Only participants with positive HBeAg at Baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HBeAg Loss at Week 24, Week 48 and Week 96</title>
          <description>The number of participants achieving hepatitis Be antigen (HBeAg) loss at Week 24, Week 48 and Week 96 in positive HBeAg participants at Baseline were summarized. Loss of HBeAg is defined as the change of detectable HBeAg from positive to negative. The LOCF method was applied for missing values.</description>
          <population>FAS Population. Only participants with positive HBeAg at Baseline were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96</title>
        <description>The number of participants achieving HBeAg/hepatitis Be antibody (HBeAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBeAg and negative HBeAb participants at Baseline were summarized. Seroconversion to HBeAg is defined as the change of detectable antibody to HBeAg from negative to positive. The LOCF method was applied for missing values.</description>
        <time_frame>Week 24, Week 48 and Week 96</time_frame>
        <population>FAS Population. Only participants with positive HBeAg and negative HBeAb at Baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HBeAg/HBeAb Seroconversion at Week 24, Week 48 and Week 96</title>
          <description>The number of participants achieving HBeAg/hepatitis Be antibody (HBeAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBeAg and negative HBeAb participants at Baseline were summarized. Seroconversion to HBeAg is defined as the change of detectable antibody to HBeAg from negative to positive. The LOCF method was applied for missing values.</description>
          <population>FAS Population. Only participants with positive HBeAg and negative HBeAb at Baseline were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96</title>
        <description>The number of participants with hepatitis B surface antigen (HBsAg) loss at Week 24, Week 48 and Week 96 in positive HBsAg participants at Baseline were summarized. Loss of HBsAg is defined as change of detectable HBsAg from positive to negative. The LOCF method was applied for missing values.</description>
        <time_frame>Week 24, Week 48 and Week 96</time_frame>
        <population>FAS Population.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving HBsAg Loss at Week 24, Week 48 and Week 96</title>
          <description>The number of participants with hepatitis B surface antigen (HBsAg) loss at Week 24, Week 48 and Week 96 in positive HBsAg participants at Baseline were summarized. Loss of HBsAg is defined as change of detectable HBsAg from positive to negative. The LOCF method was applied for missing values.</description>
          <population>FAS Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96</title>
        <description>The number of participants with HBsAg/hepatitis B surface antibody (HBsAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBsAg and negative HBsAb participants at Baseline were summarized. HBsAg seroconversion .is defined as change of detectable antibody to HBsAg from negative to positive. The LOCF method was applied for missing values.</description>
        <time_frame>Week 24, Week 48 and Week 96</time_frame>
        <population>FAS Population. Only participants with positive HBsAg and negative HBsAb at Baseline were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving HBsAg/HBsAb Seroconversion at Week 24, Week 48 and Week 96</title>
          <description>The number of participants with HBsAg/hepatitis B surface antibody (HBsAb) seroconversion at Week 24, Week 48 and Week 96 in positive HBsAg and negative HBsAb participants at Baseline were summarized. HBsAg seroconversion .is defined as change of detectable antibody to HBsAg from negative to positive. The LOCF method was applied for missing values.</description>
          <population>FAS Population. Only participants with positive HBsAg and negative HBsAb at Baseline were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96</title>
        <description>The number of participants achieving each indicated HBsAg category (HBsAg &lt;80, 80 to 800, 800 to 8000, 8000 to 80000, and &gt;=80000) (kilo international unit per liter [KIU/L]) by study visit was summarized. The LOCF method was applied for missing values.</description>
        <time_frame>Baseline, Week 24, Week 48 and Week 96</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Each Indicated HBsAg Category at Baseline, Week 24, Week 48 and Week 96</title>
          <description>The number of participants achieving each indicated HBsAg category (HBsAg &lt;80, 80 to 800, 800 to 8000, 8000 to 80000, and &gt;=80000) (kilo international unit per liter [KIU/L]) by study visit was summarized. The LOCF method was applied for missing values.</description>
          <population>FAS Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBsAg &lt;80 KIU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 80-800 KIU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 800-8000 KIU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 8000-80,000 KIU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg &gt;=80,000 KIU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg &lt;80 KIU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 80-800 KIU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 800-8000 KIU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 8000-80,000 KIU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg &gt;=80,000 KIU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg &lt;80 KIU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 80-800 KIU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 800-8000 KIU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 8000-80,000 KIU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg &gt;=80,000 KIU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg &lt;80 KIU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 80-800 KIU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 800-8000 KIU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg 8000-80,000 KIU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg &gt;=80,000 KIU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Each Indicated HBcrAg Category at Baseline, Week 24, Week 48 and Week 96</title>
        <description>The number of participants achieving each indicated hepatitis B core-related antigen (HBcrAg) category (HBcrAg &lt;3.0, 3.0 to 4.0, 4.0 to 5.0, 5.0 to 6.0, and &gt;=6.0) (Log kilo unit per liter [KU/L]) by study visit was summarized. The LOCF method was applied for missing values.</description>
        <time_frame>Baseline, Week 24, Week 48 and Week 96</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Each Indicated HBcrAg Category at Baseline, Week 24, Week 48 and Week 96</title>
          <description>The number of participants achieving each indicated hepatitis B core-related antigen (HBcrAg) category (HBcrAg &lt;3.0, 3.0 to 4.0, 4.0 to 5.0, 5.0 to 6.0, and &gt;=6.0) (Log kilo unit per liter [KU/L]) by study visit was summarized. The LOCF method was applied for missing values.</description>
          <population>FAS Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBcrAg &lt;3.0 Log KU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 3.0-4.0 Log KU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 4.0-5.0 Log KU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 5.0-6.0 Log KU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg &gt;=6.0 Log KU/L, Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg &lt;3.0 Log KU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 3.0-4.0 Log KU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 4.0-5.0 Log KU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 5.0-6.0 Log KU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg &gt;=6.0 Log KU/L, Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg &lt;3.0 Log KU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 3.0-4.0 Log KU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 4.0-5.0 Log KU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 5.0-6.0 Log KU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg &gt;=6.0 Log KU/L, Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg &lt;3.0 Log KU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 3.0-4.0 Log KU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 4.0-5.0 Log KU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg 5.0-6.0 Log KU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBcrAg &gt;=6.0 Log KU/L, Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Virological Breakthrough Through End of the Study</title>
        <description>The number of participants who experienced virological breakthrough was summarized. Virological breakthrough is defined as serum HBV DNA level increase &gt;=1 log10 copies/mL above the treatment nadir. Virological breakthrough values were presented from Baseline to through out the study. Baseline is defined as the value at Week 0 visit.</description>
        <time_frame>From Baseline to throughout study</time_frame>
        <population>FAS Population</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Virological Breakthrough Through End of the Study</title>
          <description>The number of participants who experienced virological breakthrough was summarized. Virological breakthrough is defined as serum HBV DNA level increase &gt;=1 log10 copies/mL above the treatment nadir. Virological breakthrough values were presented from Baseline to through out the study. Baseline is defined as the value at Week 0 visit.</description>
          <population>FAS Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Resistance Related Mutations at Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to Throughout the Study)</title>
        <description>The development of drug resistance-related (RA) mutations was analyzed to look for resistance to Lamivudine (LAM), Adefovir dipivoxil (ADV), and/or ETV in a case where a virologic breakthrough has been observed after starting the study treatment (serum HBV DNA level has increased from the nadir by at least 1 log10 copies/mL) or where the serum HBV DNA level is not less than the HBV DNA detection limit (2.1 log10 copies/mL) at Week 24, Week 48 and Week 96. Virologic breakthrough was defined as 1.0 log10 or greater increases in serum HBV-DNA levels from on-treatment nadir. Participants who achieved the HBV-DNA values below lower limit of quantification (LLQ) (&lt; 2.1 log10 copies/mL) in quantitative analysis at entire the study were also considered &quot;Negative&quot; in drug-resistance without implementation of genotypic analysis. Resistance mutation values were presented from Baseline to throughout the study. Baseline is defined as the value at Week 0 visit.</description>
        <time_frame>Screening, Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to throughout the study)</time_frame>
        <population>FAS Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>TDF 300 mg OD</title>
            <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ETV 0.5 mg OD</title>
            <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Resistance Related Mutations at Week 24, Week 48, Week 96 and Virological Breakthrough (Baseline to Throughout the Study)</title>
          <description>The development of drug resistance-related (RA) mutations was analyzed to look for resistance to Lamivudine (LAM), Adefovir dipivoxil (ADV), and/or ETV in a case where a virologic breakthrough has been observed after starting the study treatment (serum HBV DNA level has increased from the nadir by at least 1 log10 copies/mL) or where the serum HBV DNA level is not less than the HBV DNA detection limit (2.1 log10 copies/mL) at Week 24, Week 48 and Week 96. Virologic breakthrough was defined as 1.0 log10 or greater increases in serum HBV-DNA levels from on-treatment nadir. Participants who achieved the HBV-DNA values below lower limit of quantification (LLQ) (&lt; 2.1 log10 copies/mL) in quantitative analysis at entire the study were also considered &quot;Negative&quot; in drug-resistance without implementation of genotypic analysis. Resistance mutation values were presented from Baseline to throughout the study. Baseline is defined as the value at Week 0 visit.</description>
          <population>FAS Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LAM RA mutations, Screening, n=109, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADV RA mutations, Screening, n=109, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ETV RA mutations, Screening, n=109, 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAM RA mutations, Week 24, n=49, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADV RA mutations, Week 24, n=49, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ETV RA mutations, Week 24, n=49, 34</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAM RA mutations, Week 48, n=23, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADV RA mutations, Week 48, n=23, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ETV RA mutations, Week 48, n=23, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAM RA mutations, Week 96, n=11, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADV RA mutations, Week 96, n=11, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ETV RA mutations, Week 96, n=11, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="NA">Participants assigned to the arm ETV 0.5 mg OD completed the study at Week 48; therefore, there are no results for Week 96.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAM RA mutations, Virologic Breakthrough, n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADV RA mutations, Virologic Breakthrough, n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ETV RA mutations, Virologic Breakthrough, n=2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the treatment period (up to average of 96 weeks).</time_frame>
      <desc>SAEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who received at least one dose of investigational product.</desc>
      <group_list>
        <group group_id="E1">
          <title>TDF 300 mg OD</title>
          <description>Participants received TDF 300 mg tablet OD and ETV placebo capsule OD for 96 weeks.</description>
        </group>
        <group group_id="E2">
          <title>ETV 0.5 mg OD</title>
          <description>Participants received ETV 0.5 mg capsule OD and TDF placebo tablet OD for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="56"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

